Page last updated: 2024-11-04

vorinostat and Carcinoma, Anaplastic

vorinostat has been researched along with Carcinoma, Anaplastic in 17 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma."9.16Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. ( Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A, 2012)
"This multi-institutional phase II trial assessed the activity and toxicity of a new histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid--SAHA) in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma."9.13A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( Bender, DP; Hoffman, JS; Modesitt, SC; Sill, M, 2008)
"A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), was tested in nasopharyngeal carcinoma (NPC), both in vitro and in vivo."7.79Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. ( Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW, 2013)
"Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma."5.16Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. ( Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A, 2012)
"This multi-institutional phase II trial assessed the activity and toxicity of a new histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid--SAHA) in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma."5.13A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( Bender, DP; Hoffman, JS; Modesitt, SC; Sill, M, 2008)
"A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), was tested in nasopharyngeal carcinoma (NPC), both in vitro and in vivo."3.79Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. ( Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW, 2013)
" We found that 4 histone deacetylase inhibitors, trichostatin A (TSA), sodium butyrate (SB), valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), all significantly induced EBV lytic cycle in EBV-positive gastric carcinoma cells (AGS/BX1, latency II) but only weakly induced in Burkitt lymphoma cells (AK2003, latency I) and did not induce in lymphoblastoid cells (LCLs, latency III)."3.76Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. ( Chiang, AK; Hui, KF, 2010)
"Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis."1.42Histone deacetylase inhibitor for NUT midline carcinoma. ( Bell, D; Christensen, AM; Maher, OM; Tarek, N; Yedururi, S, 2015)
"In an in vivo tumor carcinomatosis model, the growth of transplanted SKOV-3 cells was inhibited by 71% after treatment with MHY218 (10 mg/kg), whereas SAHA (25 mg/kg) suppressed growth by 48%."1.36Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells. ( Ahn, MY; Chun, P; Jeon, HS; Jung, JH; Kim, HS; Kim, J; Kim, TH; Kim, WH; Moon, HR; Park, JH, 2010)
"In most patients with ovarian cancer, diagnosis occurs after the tumour has disseminated beyond the ovaries."1.33Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. ( Beck, JF; Belau, A; Gänge, J; Lorenz, G; Ohlinger, R; Pilz, S; Sonnemann, J; Stötzer, C, 2006)
"Murine erythroleukemia cells developed for resistance to SAHA are cross-resistant to trichostatin A, a known deacetylase inhibitor and differentiation inducer, but are not cross-resistant to HMBA."1.30A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. ( Breslow, R; Emiliani, S; Marks, PA; Richon, VM; Rifkind, RA; Verdin, E; Webb, Y, 1998)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.88)18.2507
2000's6 (35.29)29.6817
2010's10 (58.82)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jiao, J1
Fang, H1
Wang, X1
Guan, P1
Yuan, Y1
Xu, W1
Hui, KF3
Lam, BH1
Ho, DN2
Tsao, SW1
Chiang, AK3
Maher, OM1
Christensen, AM1
Yedururi, S1
Bell, D1
Tarek, N1
Carew, JS1
Medina, EC1
Esquivel, JA1
Mahalingam, D1
Swords, R1
Kelly, K1
Zhang, H1
Huang, P1
Mita, AC1
Mita, MM1
Giles, FJ1
Nawrocki, ST1
Palmieri, D1
Lockman, PR1
Thomas, FC1
Hua, E1
Herring, J1
Hargrave, E1
Johnson, M1
Flores, N1
Qian, Y1
Vega-Valle, E1
Taskar, KS1
Rudraraju, V1
Mittapalli, RK1
Gaasch, JA1
Bohn, KA1
Thorsheim, HR1
Liewehr, DJ1
Davis, S1
Reilly, JF1
Walker, R1
Bronder, JL1
Feigenbaum, L1
Steinberg, SM1
Camphausen, K1
Meltzer, PS1
Richon, VM3
Smith, QR1
Steeg, PS1
Borbone, E1
Berlingieri, MT1
De Bellis, F1
Nebbioso, A1
Chiappetta, G1
Mai, A1
Altucci, L1
Fusco, A1
Jeon, HS1
Ahn, MY1
Park, JH1
Kim, TH1
Chun, P1
Kim, WH1
Kim, J1
Moon, HR1
Jung, JH1
Kim, HS1
Li, X1
Kaplun, A1
Lonardo, F1
Heath, E1
Sarkar, FH1
Irish, J1
Sakr, W1
Sheng, S1
Millward, M1
Price, T1
Townsend, A1
Sweeney, C1
Spencer, A1
Sukumaran, S1
Longenecker, A1
Lee, L1
Lay, A1
Sharma, G1
Gemmill, RM1
Drabkin, HA1
Lloyd, GK1
Neuteboom, ST1
McConkey, DJ1
Palladino, MA1
Spear, MA1
Tsang, CM1
Middeldorp, JM1
Tsao, GS1
Dom, G1
Galdo, VC1
Tarabichi, M1
Tomás, G1
Hébrant, A1
Andry, G1
De Martelar, V1
Libert, F1
Leteurtre, E1
Dumont, JE1
Maenhaut, C1
van Staveren, WC1
Mitsiades, CS1
Poulaki, V1
McMullan, C1
Negri, J1
Fanourakis, G1
Goudopoulou, A1
Marks, PA2
Mitsiades, N1
Sonnemann, J1
Gänge, J1
Pilz, S1
Stötzer, C1
Ohlinger, R1
Belau, A1
Lorenz, G1
Beck, JF1
Luong, QT1
O'Kelly, J1
Braunstein, GD1
Hershman, JM1
Koeffler, HP1
Modesitt, SC1
Sill, M1
Hoffman, JS1
Bender, DP1
Emiliani, S1
Verdin, E1
Webb, Y1
Breslow, R1
Rifkind, RA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833]Phase 1/Phase 29 participants (Actual)Interventional2014-04-30Terminated (stopped due to Closed by Sponsor)
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]Phase 16 participants (Actual)Interventional2016-03-31Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for vorinostat and Carcinoma, Anaplastic

ArticleYear
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carci

2012
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2008, Volume: 109, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Disease-Free Survival; Female; Gas

2008

Other Studies

15 other studies available for vorinostat and Carcinoma, Anaplastic

ArticleYear
Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colo

2009
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Line

2013
Histone deacetylase inhibitor for NUT midline carcinoma.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:4

    Topics: Adolescent; Carcinoma; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mandibular

2015
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
    Journal of cellular and molecular medicine, 2010, Volume: 14, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma; Cell Lin

2010
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood-Brain Barrier; Brain Neoplasms; Breast Neop

2009
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
    Oncogene, 2010, Jan-07, Volume: 29, Issue:1

    Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Carcinoma; Cell Line; Cell Line, Tumor; Cell Prol

2010
Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
    International journal of cancer, 2010, May-15, Volume: 126, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Butyrates; Carcinoma; Cell Cy

2010
Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
    International journal of oncology, 2010, Volume: 37, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Cell Survival; Dose-Response Relati

2010
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.
    Molecular cancer research : MCR, 2011, Volume: 9, Issue:6

    Topics: Carcinoma; Cell Line, Tumor; Cell Survival; Gene Silencing; Glutathione S-Transferase pi; Histone De

2011
Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
    International journal of cancer, 2012, Oct-15, Volume: 131, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Cell Proliferation; Epstein

2012
5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.
    Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma; Cell Differentiation; Cell Line,

2013
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-15, Volume: 11, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Death; Cinnamates; Down-Regulation; Gene Expressio

2005
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    BMC cancer, 2006, Jul-11, Volume: 6

    Topics: Acetylation; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Caspase 3; Caspase

2006
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-15, Volume: 12, Issue:18

    Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma; Cell Cycle Pr

2006
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Mar-17, Volume: 95, Issue:6

    Topics: Acetamides; Animals; Carcinoma; Cell Differentiation; Cell Line, Transformed; Cell Transformation, N

1998